Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: A positron emission tomography study using carbon 11-labeled carfentanil

Archives of General Psychiatry

Volumn 62, Issue 1, 2005, Pages 57-64

  Heinz, Andreas ^a   Reimold, Matthias ^b   Wrase, Jana ^a   Hermann, Derik ^c   Croissant, Bernhard ^c   Mundle, Götz ^b   Dohmen, Bernhard M ^b   Braus, Dieter H ^c   Schumann, Gunter ^c   Machulla, Hans Jürgen ^b   Bares, Roland ^b   Mann, Karl ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CARFENTANIL; MU OPIATE RECEPTOR;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; FOLLOW UP; HUMAN; IN VIVO STUDY; MALE; NUCLEUS ACCUMBENS; OBSESSION; POSITRON EMISSION TOMOGRAPHY; RATING SCALE; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; BASAL GANGLIA; BEHAVIOR, ADDICTIVE; CARBON RADIOISOTOPES; FENTANYL; HOSPITALIZATION; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, OPIOID, MU; SEVERITY OF ILLNESS INDEX; TEMPERANCE;

EID: 19944426685     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.62.1.57     Document Type: Article

References (41)

1. Zhang M, Kelley AE. Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens. Psychopharmacology (Berl). 2002;159:415-423.
2. Pecina S, Berridge KC. Opioid site in nucleus accumbens shell mediates eating and hedonic "liking" for food: map based on microinjection Fos plumes. Brain Res. 2000;863:71-86.
3. Cowen MS, Lawrence AJ. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1171-1212.
4. Marinelli PW, Kiianmaa K, Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci. 2000;66:1915-1927.
5. de Waele JP, Kiianmaa K, Gianoulakis C. Spontaneous and ethanol-stimulated in vitro release of β-endorphin by the hypothalamus of AA and ANA rats. Alcohol Clin Exp Res. 1994;18:1468-1473.
6. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152:613-615.
7. O'Malley SS, Croop RS, Wroblewski JM, Labriola DF, Volpicelli JR. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann. 1995;25:681-688.
8. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kaempf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry. 2003;60:92-99.
9. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
10. Gastpar M, Bonnet U, Boening J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22:592-598.
11. Haber SN, McFarland NR. The concept of the ventral striatum in nonhuman primates. Ann N Y Acad Sci. 1999;877:33-48.
12. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21:1034-1057.
13. Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53:225-231.
14. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen. New York: Biometrics Research, New York State Psychiatric Institute: 2001.
15. Stockwell T, Hodgson R, Edwards G, Taylor C, Rankin H. The development of a questionnaire to measure severity of alcohol dependence. Br J Addict Alcohol Other Drugs. 1979;74:79-87.
16. Skinner HA, Sheu WJ. Reliability of alcohol use indices: the Lifetime Drinking History and the MAST. J Stud Alcohol. 1982;43:1157-1170.
17. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press Inc; 1997.
18. Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA, Ravert HT, Crozier WC, Wagner HN Jr. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab. 1989;9:398-409.
19. Hiller JM, Fan LQ. Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Neurochem Res. 1996;21:1333-1345.
20. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods. 2002;27:287-299.
21. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
22. 11C]carfentanil: reference tissue methods. Nucl Med Biol. 2003;30:177-186.
23. Varga J, Szabo Z. Modified regression model for the Logan plot. J Cereb Blood Flow Metab. 2002;22:240-244.
24. Reimold M, Mueller-Schauenburg W, Becker GA, Reischl G, Dohmen BM, Bares R. Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. Eur J Nucl Med Mol Imaging. 2004;31:564-577.
25. Ashburner J, Friston K. Multimodal image coregistration and partitioning: a unified framework. Neuroimage. 1997;6:209-217.
26. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS. Regional μ opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311-315.
27. 11C]-carfentanil and positron emission tomography (PET). Pain. 2002;99:589-598.
28. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998;95:9608-9613.
29. Zubieta JK, Heitzeg MM, Smith YR, Bueler JA, Xu K, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243.
30. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386:827-830.
31. Breiter H, Aharon I, Kahneman D, Dale A, Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron. 2001;30:619-639.
32. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247-291.
33. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52-58.
34. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci. 2002;22:3312-3320.
35. 2 receptor density in Fawn-Hooded rat brain. J Pharmacol Exp Ther. 2002;302:551-559.
36. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996;2:1225-1229.
37. Narendran R, Talbot PS, Kegeles LS, Martinez D, Huang Y, Ngo K, Hackett E, Castrillon J, Abi-Dargham A, Laruelle M, Hwang DR. In vivo vulnerability to endogenous dopamine: comparison of the dopamine-2 (D2) agonist tracer [11C]N-propylnorapomorphine ([11C]NPA) with the D2 antagonist tracer [11C]raclopride. Synapse. 2004;52(3):188-208.
38. Ciccocioppo R, Martin-Fardon R, Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behaviour by drug-associated stimuli in rats. Neuropsychopharmacology. 2002;27:391-399.
39. Pfefferbaum A, Sullivan EV, Rosenbloom MJ, Mathalon DH, Lim KO. A controlled study of cortical gray matter and ventricular changes in alcoholic men over a 5-year interval. Arch Gen Psychiatry. 1998;55:905-912.
40. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects and dependence in μ-opioid receptor knock-out mice. J Neurosci. 2002;22:10935-10940.
41. Durcan MJ, Morgan PF. Opioid receptor mediation of hypothermic response to caffeine. Eur J Pharmacol. 1992;224:151-156.